Targeting TAM Receptors: A New Frontier in Rheumatoid Arthritis treatment
Rheumatoid arthritis (RA), a chronic autoimmune disease causing painful joint inflammation, is increasingly being understood thru the lens of Tyro3, Axl, and MerTK – a family of receptor tyrosine kinases known as TAM receptors. Emerging research suggests these receptors play a surprisingly complex, and potentially pivotal, role in RA progress and progression, opening up exciting new avenues for therapeutic intervention.
For years, the focus in RA treatment has centered on broadly suppressing the immune system. However, a more nuanced approach – one that modulates immune response rather than simply dampening it - is gaining traction. This is where TAM receptors come in.
The Dichotomy of TAM Receptors in RA
Recent studies reveal a captivating duality within the TAM receptor family. While Axl and MerTK appear to offer protective benefits against RA,Tyro3 seems to actively exacerbate inflammation and contribute to joint destruction. This functional difference is key.
As detailed in a recent Cell Biosci publication (Dai et al., 2025), researchers propose distinct therapeutic strategies:
* Activate Axl/MerTK: boosting these pathways could help restore immune balance.
* Inhibit Tyro3: Blocking Tyro3 could directly reduce synovitis (inflammation of the joint lining) and bone erosion.
This isn’t just theoretical.Research, including work by Waterborg et al. (2018) in PLoS One, demonstrates that mice lacking Tyro3, Axl, and MerTK develop bone marrow edema – an early indicator of RA pathology.Further, Gao et al. (2023) in Cell Dialog and Signaling showed differential contributions of these receptors to antibody-induced arthritis, solidifying their distinct roles.
Soluble TAM Receptors: Potential Biomarkers for RA
Beyond direct therapeutic targets, TAM receptors are also showing promise as biomarkers. Soluble forms of these receptors (sTAMs) are released into synovial fluid – the fluid surrounding joints – and are significantly elevated in RA patients.
These sTAMs, generated by enzymatic cleavage, could provide valuable insights into:
* Disease Activity: Tracking sTAM levels could help assess how active the disease is.
* Severity: Higher levels may correlate with more severe RA.
* Prognosis: sTAM levels could potentially predict disease progression.
Specifically, elevated serum sTyro3 levels have been linked to systemic inflammation. However, standardized detection methods are crucial. Further research is needed to validate these findings and establish reliable diagnostic tools.
The Pipeline of TAM-Targeted Therapies
The potential of TAM receptors hasn’t gone unnoticed by the pharmaceutical industry. Currently, approximately 20 small-molecule TAM inhibitors are in clinical evaluation, with 15 still actively being developed.
While much of the initial focus has been on oncology – where TAM receptors play a role in drug resistance – the underlying mechanisms suggest these therapies could be repurposed for autoimmune diseases like RA. These inhibitors primarily work by:
* Blocking Receptor-Ligand Binding: Preventing the receptors from being activated.
* Suppressing Kinase Activity: Interfering with the signaling pathways downstream of the receptors.
Furthermore, a diverse range of additional small-molecule inhibitors are in the preclinical stage, demonstrating a growing commitment to exploring TAM-targeting strategies.
Looking Ahead: Precision and Combination Therapies
The future of TAM-targeted therapies in RA hinges on a few key areas:
* Receptor Specificity: Developing modulators that target individual TAM receptors, overcoming the structural similarities between them.
* Combination Strategies: Combining TAM-targeted therapies with existing RA treatments to maximize efficacy.
* Deepened understanding: Continued research to unravel the complex interplay between TAM signaling and different stages of RA.
Ultimately,a complete understanding of TAM receptor signaling,coupled with innovative therapeutic approaches,holds the potential to revolutionize RA treatment,moving beyond broad immunosuppression towards more targeted and effective interventions.
References:
- Dai M, Yang X, Yao F, et al. From pathogenesis to therapeutic targeting: new insight into TAM receptors in rheumatoid arthritis. Cell Biosci. 2025;15(1):157. Published 2025 Nov 19. doi:10.1186/s13578-025-01503-w
- Waterborg CEJ, Koenders MI, van